Advanced Neuroprotective Strategies in Multiple Sclerosis: A Randomized Controlled Trial of Targeted Immunomodulatory Therapy
Delving into the heart of neurology, our dedicated study combines cutting-edge research with a passion for discovery.
We are on a mission to uncover groundbreaking treatments for Multiple Sclerosis (MS), aiming to provide not only medical advancements but also a renewed sense of hope for individuals affected by this condition.
Our goal is to contribute to an improved quality of life, pushing the boundaries of what's possible in the realm of neurology and opening new avenues for those impacted by MS.
See if you are Eligible Now ↓
Eligibility Criteria
We are seeking individuals who:
- Are between 18 and 70 years of age
- A medical diagnosis of MS was confirmed by a neurologist.
- Ability to stand independently without any aid for at least 3 minutes.
- English or Spanish speaking.
- Located in or within 25 miles of Miami, Florida.
Non-Eligibility Factors:
- MS-related exacerbation or medication change in the past two months.
- Unable to perform the experimental tasks.
If you do not meet the criteria, we would greatly appreciate your assistance in sharing the study:
Why Participate?
Your involvement has the power to influence groundbreaking research and drive innovation, helping us to turn today's discoveries into tomorrow's solutions.
Your participation is more than just a contribution to our study; it's a vital step forward in the quest to combat Multiple Sclerosis. Each individual's experience offers unique insights that are crucial in shaping the future of MS treatment. By joining our study, you become a pivotal part of a collective effort to unlock new possibilities in medical science and offer hope to millions.
Participant Compensation
Participants in this study will be compensated for their time and contribution to this important research.
Compensation will include a stipend to cover travel and incidental expenses, with additional provisions made for any extended participation requirements. Our commitment is to support our participants' dedication to advancing MS research, ensuring that their involvement is acknowledged and valued.
For specific details regarding compensation amounts and schedules, please contact our study coordinator, Paul Vargas, directly.
Who is running the study?
Dr. Samantha Example, MD, PhD
Dr. Example, a pioneering figure in multiple sclerosis (MS) research, has dedicated her career to advancing our understanding of this complex condition. Her groundbreaking work has led to significant developments in MS treatment and patient care. Renowned for her innovative approaches, she continues to inspire and lead in the field of neurology. Dr. Example's contributions have been recognized globally, solidifying her status as a leading expert in MS research.
Paul Vargas, Study Coordinator
Paul Vargas is an esteemed Study Coordinator with a robust background in neurological research, particularly in Multiple Sclerosis. With a Master's in Public Health and years of experience managing clinical trials, he brings a wealth of knowledge and a meticulous eye for detail to our groundbreaking MS study. His dedication to patient care and clinical excellence ensures that every aspect of the study is conducted with the highest standards of efficacy and ethics, ensuring that the data collected will pave the way for future innovations in MS therapy. His compassionate approach and commitment to research integrity make him a cornerstone of our research team.
Study Summary
The trial is a pioneering venture in the field of Multiple Sclerosis (MS) research, focusing on evaluating the effectiveness of a novel immunomodulatory drug. Paul Vargas, as the Study Coordinator, ensures the trial's integrity and adherence to the highest scientific standards. This randomized controlled trial aims to halt or reverse the progression of neurological symptoms in MS patients, potentially offering a significant improvement in their quality of life. Through rigorous testing and patient monitoring, the study hopes to contribute meaningful insights into MS treatment and potentially usher in a new era of personalized medicine for this challenging condition.
Study Timeline
The study's timeline showcases a systematic progression from initiation to publication within a year.
- January 2024: Study recruitment begins.
- March 2024: Recruitment ends.
- July 2024: Interviews are completed.
- August 2024: Data processing is concluded.
- October 2024: Data analysis is completed.
- January 2025: Findings are published.
Frequently asked questions
Our study is designed to evaluate the efficacy and safety of a new immunomodulatory treatment for MS. We aim to improve symptom management, reduce the frequency of relapses, and enhance overall patient well-being.
Individuals diagnosed with Multiple Sclerosis who meet specific health criteria outlined in our selection parameters may be eligible. A full list of criteria can be found on our website, or you can contact our study coordinator, Paul Vargas, for a pre-screening.
Participants will undergo a series of assessments, including MRI scans, neurological evaluations, and regular health monitoring. They will receive the study medication or a placebo and will be closely followed for changes in their symptoms and overall health.
We adhere to strict confidentiality protocols compliant with HIPAA regulations. All personal information and medical data are encrypted and accessible only to authorized study personnel. Participant identities will not be disclosed in any reports or publications resulting from this study.
Contact us if you have any specific questions or special inquiries. We're here to assist you!
Take the first step towards change - Apply to the study now! Your involvement could be the key to unlocking new possibilities for individuals living with MS.
Copyright © 2023 Landmark Associates, Inc. All rights reserved. Unauthorized duplication or distribution of this content is strictly prohibited. The information on this website is for informational purposes only; it is deemed accurate but not guaranteed. All information is subject to change at any time without notice.